Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End
· seekingalpha.com
Oruka Therapeutics stock outlook: ORKA-001 ultra-long-acting psoriasis data (PASI 100/90), cash runway, and catalysts. Click for more on ORKA stock.
Most of the conversation around Oruka Therapeutics ( ORKA ) focuses on just one point: ORKA-001 is an IL-23p19 antibody that does what Skyrizi does with much le...